07:00 , Jul 16, 2015 |  BC Innovations  |  Product R&D

Many flavors to S1P

While this week's $7.2 billion acquisition by Celgene Corp. of Receptos Inc. and its Phase III S1PR1 modulator Ozanimod might reflect the target's potential in ulcerative colitis (UC) and multiple sclerosis (MS), a host of...